Apremilast Adherence and Persistence in Patients with Psoriasis and Psoriatic Arthritis in the Telehealth Setting Versus the In-person Setting During the COVID-19 Pandemic

Autor: Ashis K. Das, Eunice Chang, Caleb Paydar, Michael S. Broder, Kate K. Orroth, Myriam Cordey

Publikováno v: Dermatology and Therapy, Vol 13, Iss 9, Pp 1973-1984 (2023)

Abstract Introduction Limited access to healthcare during the COVID-19 pandemic prompted patients to seek care using telehealth. In this study, we assessed whether treatment patterns differed for patients with psoriasis (PsO) or psoriatic arthritis (

Externí odkaz: https://doaj.org/article/c34a4c499dbb4b3fbf5ca771e8b33e2d

Risk for recurrent cardiovascular disease events among patients with diabetes and chronic kidney disease

Autor: Demetria Hubbard, Lisandro D. Colantonio, Robert S. Rosenson, Todd M. Brown, Elizabeth A. Jackson, Lei Huang, Kate K. Orroth, Stephanie Reading, Mark Woodward, Vera Bittner, Orlando M. Gutierrez, Monika M. Safford, Michael E. Farkouh, Paul Muntner

Publikováno v: Cardiovascular Diabetology, Vol 20, Iss 1, Pp 1-9 (2021)

Abstract Background Adults who have experienced multiple cardiovascular disease (CVD) events have a very high risk for additional events. Diabetes and chronic kidney disease (CKD) are each associated with an increased risk for recurrent CVD events fo

Externí odkaz: https://doaj.org/article/b2266f52c5094a4091cdd331dbc82fba

The Projected Impact of Population-Wide Achievement of LDL Cholesterol <70 mg/dL on the Number of Recurrent Events Among US Adults with ASCVD

Autor: Vera Bittner, Emily C. McKinley, Michael E. Farkouh, Stephanie R. Reading, Ligong Chen, Emily B. Levitan, Jason Exter, Monika M. Safford, Lei Huang, Robert S. Rosenson, Kate K. Orroth, Mark Woodward, Lisandro D. Colantonio, Elizabeth A. Jackson, Todd M. Brown, Paul Muntner

Publikováno v: Cardiovascular Drugs and Therapy. 37:107-116

Adults with atherosclerotic cardiovascular disease (ASCVD) are recommended high-intensity statins, with those at very high risk for recurrent events recommended adding ezetimibe and/or a proprotein convertase subtilisin/kexin type 9 inhibitor if thei

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::ee90307815361c52d9d69f4f1a274ff0
https://doi.org/10.1007/s10557-021-07268-x

Use of negative control outcomes to assess the comparability of patients initiating lipid-lowering therapies

Autor: Sara N. Levintow, Kate K. Orroth, Alexander Breskin, Andrew S. Park, Jose H. Flores‐Arredondo, Paul Dluzniewski, Ann Marie Navar, Henrik T. Sørensen, M. Alan Brookhart

Publikováno v: Levintow, S N, Orroth, K K, Breskin, A, Park, A S, Flores-Arredondo, J H, Dluzniewski, P, Navar, A M, Sørensen, H T & Brookhart, M A 2022, ' Use of negative control outcomes to assess the comparability of patients initiating lipid-lowering therapies ', Pharmacoepidemiology and Drug Safety, vol. 31, no. 4, pp. 383-392 . https://doi.org/10.1002/pds.5396

Purpose: Clinical trials have demonstrated efficacy of proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) in reducing risk of cardiovascular disease events, but effectiveness in routine clinical care has not been well-studied. We used

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e8fa31e08553aa966cb8dbf6bff66b28
https://pure.au.dk/portal/da/publications/use-of-negative-control-outcomes-to-assess-the-comparability-of-patients-initiating-lipidlowering-therapies(cfe9a6c5-f11d-4cc0-9c39-7a7acc3bb2a4).html

Factors associated with time to initiation of a PCSK9 inhibitor after hospital discharge for acute myocardial infarction

Autor: Robert S. Rosenson, Jason Exter, Lisandro D. Colantonio, Emily C. McKinley, Vera Bittner, Paul Muntner, Ligong Chen, Stephanie R. Reading, Kate K. Orroth, Todd M. Brown

Publikováno v: Journal of clinical lipidology. 16(1)

Background Proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) lower atherosclerotic cardiovascular disease (ASCVD) event risk. Objective Analyze patient characteristics associated with time to PCSK9i initiation following an acute myoca

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::44ac8fd5db2c00b5a8d49100394ea87a
https://pubmed.ncbi.nlm.nih.gov/34848176